|
1
|
Ohgaki H, Dessen P, Jourde B, Horstmann S,
Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM,
Maiorka PC, et al: Genetic pathways to glioblastoma: A
population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohgaki H and Kleihues P: Population-based
studies on incidence, survival rates and genetic alterations in
astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol.
64:479–489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bauchet L, Mathieu-Daudé H, Fabbro-Peray
P, Rigau V, Fabbro M, Chinot O, Pallusseau L, Carnin C, Lainé K,
Schlama A, et al: Oncological patterns of care and outcome for 952
patients with newly diagnosed glioblastoma in 2004. Neuro Oncol.
12:725–735. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stewart LA: Chemotherapy in adult
high-grade glioma: A systematic review and meta-analysis of
individual patient data from 12 randomised trials. Lancet.
359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bokstein F, Shpigel S and Blumenthal DT:
Treatment with bevacizumab and irinotecan for recurrent high-grade
glial tumors. Cancer. 112:2267–2273. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedman HS, Prados MD, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, et al: Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kreisl TN, Kim L, Moore K, Duic P, Royce
C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al:
Phase II trial of single-agent bevacizumab followed by bevacizumab
plus irinotecan at tumor progression in recurrent glioblastoma. J
Clin Oncol. 27:740–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reardon DA and Wen PY: Therapeutic
advances in the treatment of glioblastoma: Rationale and potential
role of targeted agents. Oncologist. 11:152–164. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vredenburgh JJ, Desjardins A, Herndon JE
II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S,
Gururangan S, Sampson J, et al: Bevacizumab plus irinotecan in
recurrent glioblastoma multiforme. J Clin Oncol. 25:4722–4729.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kanu OO, Mehta A, Di C, Lin N, Bortoff K,
Bigner DD, Yan H and Adamson DC: Glioblastoma multiforme: A review
of therapeutic targets. Expert Opin Ther Targets. 13:701–718. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smrdel U, Kovac V, Popovic M and Zwitter
M: Glioblastoma patients in Slovenia from 1997 to 2008. Radiol
Oncol. 48:72–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rosenthal MA, Drummond KJ, Dally M, Murphy
M, Cher L, Ashley D, Thursfield V and Giles GG: Management of
glioma in Victoria (1998–2000): Retrospective cohort study. Med J
Aust. 184:270–273. 2006.PubMed/NCBI
|
|
14
|
Gutenberg A, Bock HC, Reifenberger G,
Brück W and Giese A: Toxicity and survival in primary glioblastoma
patients treated with concomitant plus adjuvant temozolomide versus
adjuvant temozolomide: Results of a single-institution,
retrospective, matched-pair analysis. Acta Neurochir (Wien).
155:429–435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stummer W, Meinel T, Ewelt C, Martus P,
Jakobs O, Felsberg J and Reifenberger G: Prospective cohort study
of radiotherapy with concomitant and adjuvant temozolomide
chemotherapy for glioblastoma patients with no or minimal residual
enhancing tumor load after surgery. J Neurooncol. 108:89–97. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bucci MK, Maity A, Janss AJ, Belasco JB,
Fisher MJ, Tochner ZA, Rorke L, Sutton LN, Phillips PC and Shu HK:
Near complete surgical resection predicts a favorable outcome in
pediatric patients with nonbrainstem, malignant gliomas: Results
from a single center in the magnetic resonance imaging era. Cancer.
101:817–824. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Devaux BC, O'Fallon JR and Kelly PJ:
Resection, biopsy and survival in malignant glial neoplasms. A
retrospective study of clinical parameters, therapy and outcome. J
Neurosurg. 78:767–775. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kreth FW, Thon N, Simon M, Westphal M,
Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T,
Weller M, et al: Gross total but not incomplete resection of
glioblastoma prolongs survival in the era of radiochemotherapy. Ann
Oncol. 24:3117–3123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lacroix M, Abi-Said D, Fourney DR,
Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch
SJ, Holland E, et al: A multivariate analysis of 416 patients with
glioblastoma multiforme: Prognosis, extent of resection and
survival. J Neurosurg. 95:190–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laws ER, Parney IF, Huang W, Anderson F,
Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, et
al: Survival following surgery and prognostic factors for recently
diagnosed malignant glioma: Data from the glioma outcomes project.
J Neurosurg. 99:467–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pichlmeier U, Bink A, Schackert G and
Stummer W: ALA Glioma Study Group: Resection and survival in
glioblastoma multiforme: An RTOG recursive partitioning analysis of
ALA study patients. Neuro Oncol. 10:1025–1034. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Simpson JR, Horton J, Scott C, Curran WJ,
Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO and Nelson
JS: Influence of location and extent of surgical resection on
survival of patients with glioblastoma multiforme: Results of three
consecutive radiation therapy oncology group (RTOG) clinical
trials. Int J Radiat Oncol Biol Phys. 26:239–244. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stummer W, Pichlmeier U, Meinel T,
Wiestler OD, Zanella F and Reulen HJ: ALA-Glioma Study Group:
Fluorescence-guided surgery with 5-aminolevulinic acid for
resection of malignant glioma: A randomised controlled multicentre
phase III trial. Lancet Oncol. 7:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wood JR, Green SB and Shapiro WR: The
prognostic importance of tumor size in malignant gliomas: A
computed tomographic scan study by the brain tumor cooperative
group. J Clin Oncol. 6:338–343. 1988.PubMed/NCBI
|
|
25
|
Coffey RJ, Lunsford LD and Taylor FH:
Survival after stereotactic biopsy of malignant gliomas.
Neurosurgery. 22:465–473. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Duncan GG, Goodman GB, Ludgate CM and
Rheaume DE: The treatment of adult supratentorial high grade
astrocytomas. J Neurooncol. 13:63–72. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Quigley MR and Maroon JC: The relationship
between survival and the extent of the resection in patients with
supratentorial malignant gliomas. Neurosurgery. 29:385–388. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barker CA, Chang M, Chou JF, Zhang Z, Beal
K, Gutin PH and Iwamoto FM: Radiotherapy and concomitant
temozolomide may improve survival of elderly patients with
glioblastoma. J Neurooncol. 109:391–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ewelt C, Goeppert M, Rapp M, Steiger HJ,
Stummer W and Sabel M: Glioblastoma multiforme of the elderly: The
prognostic effect of resection on survival. J Neurooncol.
103:611–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Iwamoto FM, Cooper AR, Reiner AS, Nayak L
and Abrey LE: Glioblastoma in the elderly: The memorial
sloan-kettering cancer center experience (1997–2007). Cancer.
115:3758–3766. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chaichana KL, Chaichana KK, Olivi A,
Weingart JD, Bennett R, Brem H and Quiñones-Hinojosa A: Surgical
outcomes for older patients with glioblastoma multiforme:
Preoperative factors associated with decreased survival. Clinical
article. J Neurosurg. 114:587–594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oszvald A, Güresir E, Setzer M, Vatter H,
Senft C, Seifert V and Franz K: Glioblastoma therapy in the elderly
and the importance of the extent of resection regardless of age. J
Neurosurg. 116:357–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Curran WJ Jr, Scott CB, Horton J, Nelson
JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO and
Krisch RE: Recursive partitioning analysis of prognostic factors in
three radiation therapy oncology group malignant glioma trials. J
Natl Cancer Inst. 85:704–710. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Intergroup Radiation Therapy Oncology
Group Trial 9402. Cairncross G, Berkey B, Shaw E, Jenkins R,
Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre
N, et al: Phase III trial of chemotherapy plus radiotherapy
compared with radiotherapy alone for pure and mixed anaplastic
oligodendroglioma: Intergroup radiation therapy oncology group
trial 9402. J Clin Oncol. 24:2707–2714. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van den Bent MJ, Carpentier AF, Brandes
AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC,
Grisold W, Sipos L, et al: Adjuvant procarbazine, lomustine and
vincristine improves progression-free survival but not overall
survival in newly diagnosed anaplastic oligodendrogliomas and
oligoastrocytomas: A randomized European organisation for research
and treatment of cancer phase III trial. J Clin Oncol.
24:2715–2722. 2006. View Article : Google Scholar : PubMed/NCBI
|
